| 1.64 -0.12 (-6.82%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.34 |
1-year : | 2.61 |
| Resists | First : | 2 |
Second : | 2.24 |
| Pivot price | 1.89 |
|||
| Supports | First : | 1.62 |
Second : | 1.35 |
| MAs | MA(5) : | 1.75 |
MA(20) : | 1.94 |
| MA(100) : | 1.81 |
MA(250) : | 1.88 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.4  |
D(3) : | 7.7 |
| RSI | RSI(14): 33.5 |
|||
| 52-week | High : | 3.55 | Low : | 1.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ACRV ] has closed above bottom band by 0.4%. Bollinger Bands are 1.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.75 - 1.76 | 1.76 - 1.77 |
| Low: | 1.6 - 1.61 | 1.61 - 1.63 |
| Close: | 1.62 - 1.64 | 1.64 - 1.66 |
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Wed, 07 Oct 2026
Mary Miller Executes Automatic Sale of 294 Shares at $1.99 for RSU Tax Withholding at Acrivon Therapeutics - Kalkine Media
Wed, 07 Oct 2026
Automatic tax withholding triggers a 294-share sale by Acrivon Therapeutics (ACRV) legal chief - Stock Titan
Wed, 07 Oct 2026
Acrivon Therapeutics chief legal officer sells $585 in stock By Investing.com - Investing.com UK
Wed, 07 Oct 2026
Acrivon Therapeutics chief legal officer sells $585 in stock - Investing.com
Tue, 25 Aug 2026
Acrivon (NASDAQ: ACRV) CEO may sell stock from vested RSUs - Stock Titan
Thu, 20 Aug 2026
Acrivon Therapeutics (ACRV) COO’s tax sale leaves 146,349 shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 15.3 (%) |
| Held by Institutions | 50.3 (%) |
| Shares Short | 1,620 (K) |
| Shares Short P.Month | 1,140 (K) |
| EPS | -1.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.1 % |
| Return on Equity (ttm) | -64.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -63 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -0.88 |
| PEG Ratio | 0 |
| Price to Book value | 0.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|